NasdaqGM - Delayed Quote USD

Clearside Biomedical, Inc. (CLSD)

Compare
1.3400 0.0000 (0.00%)
At close: October 2 at 4:00 PM EDT
Loading Chart for CLSD
DELL
  • Previous Close 1.3400
  • Open 1.3100
  • Bid 1.3100 x 100
  • Ask 1.3600 x 300
  • Day's Range 1.2400 - 1.3400
  • 52 Week Range 0.6500 - 2.1200
  • Volume 543,450
  • Avg. Volume 277,904
  • Market Cap (intraday) 100.159M
  • Beta (5Y Monthly) 2.36
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5000
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.57

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

clearsidebio.com

30

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CLSD

View More

Performance Overview: CLSD

Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CLSD
14.53%
S&P 500
19.70%

1-Year Return

CLSD
54.02%
S&P 500
33.15%

3-Year Return

CLSD
76.49%
S&P 500
31.04%

5-Year Return

CLSD
117.89%
S&P 500
94.19%

Compare To: CLSD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CLSD

View More

Valuation Measures

Annual
As of 10/2/2024
  • Market Cap

    100.16M

  • Enterprise Value

    71.66M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.98

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    9.52

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -44.05%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    7.52M

  • Net Income Avi to Common (ttm)

    -33.46M

  • Diluted EPS (ttm)

    -0.5000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.36M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -17.5M

Research Analysis: CLSD

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 90k
Earnings -7.59M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

4.00
5.57 Average
1.3400 Current
8.00 High
 

Company Insights: CLSD

Research Reports: CLSD

View More
  • Daily – Vickers Top Buyers & Sellers for 04/22/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 02/12/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 01/08/2021

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     

People Also Watch